Develop Three Novel Bispecific ADC Programs
13/01/2025 01:08
Jan 12 (Reuters) - Merus NV 2GH.F :
* MERUS AND BIOHAVEN ANNOUNCE COLLABORATION TO CO-DEVELOP
THREE
NOVEL BISPECIFIC ADC PROGRAMS
* BIOHAVEN LTD - CO IS RESPONSIBLE FOR PRECLINICAL ADC
GENERATION
OF THREE MERUS BISPECIFIC ANTIBODIES UNDER MUTUALLY AGREED
RESEARCH PLANS
* BIOHAVEN - AGREEMENT INCLUDES TWO MERUS BISPECIFIC
PROGRAMS
GENERATED USING BICLONICS PLATFORM
* BIOHAVEN LTD - MERUS WILL RECEIVE AN UPFRONT PAYMENT AND
LICENSE
FEE AT ADC CANDIDATE NOMINATION OF FIRST PROGRAM
Source text: ID:nGNX47y28G
Further company coverage: 2GH.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing